X

Trial Profile

Phase I Feasibility Study of ALLOSTIM(TM) in Combination With Radiofrequency Ablation in Patients With Refractory Hepatocellular Carcinoma

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs T-cell vaccine-AlloStim (Primary) ; T-cell vaccine-AlloStim (Primary) ; T-cell vaccine-AlloStim (Primary)
Indications Liver cancer
Focus Adverse reactions
Sponsors Immunovative Therapies

Most Recent Events

01 Apr 2015 According to the ClinicalTrials.gov record, status changed from not yet recruiting to withdrawn prior to enrolment.
03 Jan 2014 Planned initiation date changed from 1 Nov 2013 to 1 Jan 2014, as reported in a Tauriga Sciences media release.
20 Aug 2013 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com